[Research progress on chemokine receptor 5-targeted therapy for HIV-1].
Along with the spread of human immunodeficiency virus 1 (HIV-1) infection in the world and the emergence of drug-resistant viral strains, it is urgent to seek the novel potent therapies. Chemokine receptor 5 (CCR5) is one of the main coreceptors involved in the entry of HIV-1 into target cells. Nowadays, a number of CCR5 antagonists have been developed and some of them have progressed to clinical trials or been approved. Research progress has also been made in the CCR5-targeted gene therapy. This review summarizes the recent research progress on the CCR5-targeted drug and gene therapy.
Yan-Jie
YJ
Wang
Jan-Qiong
JQ
Zhang
D065100:CCR5 Receptor Antagonists; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D019713:Receptors, CCR5 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
D065100:CCR5 Receptor Antagonists; D019713:Receptors, CCR5